Triptorelin Research Dosage: Published Protocol Reference
Triptorelin dosage references vary by route and study context. The database lists Intramuscular depot: 3.75 mg (monthly) or 11.25 mg (3-month) or 22.5 mg (6-month), Monthly, quarterly, or semi-annually and Subcutaneous: 0.1 mg/day, Daily (short protocol for IVF). These are research-context references, not a universal protocol.
Direct Answer
Triptorelin (Trelstar) is FDA-approved for prostate cancer androgen deprivation and gender-affirming hormone therapy, with multiple Phase 3 RCTs supporting both indications. As a GnRH agonist, it produces reliable castrate-level testosterone suppression with a well-characterized adverse effect profile. For research into GnRH agonist pharmacology or testosterone suppression, it is a validated reference compound.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Prostate cancer androgen deprivation, gender-affirming hormone therapy, GnRH agonist pharmacology
Research Dosage References
- <strong>Intramuscular depot</strong> - 3.75 mg (monthly) or 11.25 mg (3-month) or 22.5 mg (6-month) - Monthly, quarterly, or semi-annually - Depot formulation provides sustained release. Prostate cancer: typically 3-month or 6-month depot. Endometriosis: usually limited to 6 months with add-back therapy.
- <strong>Subcutaneous</strong> - 0.1 mg/day - Daily (short protocol for IVF) - Used in some IVF stimulation protocols. Less common than depot formulations.
Half-Life
3-5 hours (terminal), but depot formulations maintain drug levels for 1-6 months.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Triptorelin, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Initial testosterone flare can worsen prostate cancer symptoms - consider anti-androgen cover for first 2-4 weeks
- Long-term use causes significant bone loss - monitor BMD and consider add-back therapy
- Cardiovascular risk may be increased with androgen deprivation therapy
- Hyperglycemia and diabetes risk elevated in prostate cancer patients on ADT
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Prostate Cancer Control (Level A), Endometriosis Symptom Relief (Level A), and Central Precocious Puberty Arrest (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Triptorelin Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/triptorelin-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.